Smart combo attack: new trial matches lung cancer drugs to tumor fingerprints
NCT ID NCT07172412
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing several drug combinations as a first treatment for extensive-stage small cell lung cancer. Researchers will assign 165 participants to different treatment arms based on specific biomarkers in their tumors. The goal is to see if matching therapy to these markers improves outcomes like tumor shrinkage and survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Selinexor, Anlotinib, DLL3 CAR-NK cells, Etoposide + Cisplatin/Carboplatin, and immunotherapies (Tislelizumab, Atezolizumab, Durvalumab, Benmelstobart, Toripalimab, Serplulimab)
- What this could lead to
- If successful, this could point toward more personalized, effective first-line treatments for extensive-stage small cell lung cancer, potentially improving survival and quality of life.
- What could go wrong
- This is an early-phase (2) trial with a small sample size (165), so results may not apply broadly. Combination therapies also carry higher risks of side effects, and the experimental arms may not outperform standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE STAGE LUNG SMALL CELL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China 300060
Tianjin, Tianjin Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.